Researchers have identified a biomarker that predicts which stage II colon cancer patients may benefit from adjuvant chemotherapy to prevent a disease recurrence.
Dr. Ravi P. Kiran has been named chief and program director of the Division of Colorectal Surgery at NewYork-Presbyterian/Columbia University Medical Center.